| Original language | English (US) |
|---|---|
| Pages (from-to) | e59 |
| Journal | Journal of the American College of Cardiology |
| Volume | 81 |
| Issue number | 8 |
| DOIs | |
| State | Published - Feb 28 2023 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 81, No. 8, 28.02.2023, p. e59.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply
T2 - Malignant Hypertensive Cardiomyopathy: Definition Matters
AU - Ascher, Simon B.
AU - de Lemos, James A.
AU - Lee, Min Jae
AU - Berry, Jarett D.
N1 - Funding Information: Dr de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics; has received consulting fees from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Cardiovascular, Inc, and Siemen's Health Care Diagnostics; and has been named a co-owner on a patent awarded to the University of Maryland (U.S. Patent Application Number: 15/309,754) entitled: “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr Berry has received grant support from the National Institutes of Health, Roche Diagnostics, and Abbott Diagnostics; and has received consulting fees from Roche Diagnostics and the Cooper Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: Dr de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics; has received consulting fees from Roche Diagnostics, Abbott Diagnostics, Ortho Clinical Diagnostics, Quidel Cardiovascular, Inc, and Siemen’s Health Care Diagnostics; and has been named a co-owner on a patent awarded to the University of Maryland (U.S. Patent Application Number: 15/309,754) entitled: “Methods for Assessing Differential Risk for Developing Heart Failure.” Dr Berry has received grant support from the National Institutes of Health, Roche Diagnostics, and Abbott Diagnostics; and has received consulting fees from Roche Diagnostics and the Cooper Institute. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2023/2/28
Y1 - 2023/2/28
UR - http://www.scopus.com/inward/record.url?scp=85147994020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147994020&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.12.015
DO - 10.1016/j.jacc.2022.12.015
M3 - Letter
C2 - 36813382
AN - SCOPUS:85147994020
SN - 0735-1097
VL - 81
SP - e59
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 8
ER -